Figure 3 | Scientific Reports

Figure 3

From: Active ingredients Isorhamnetin of Croci Srigma inhibit stomach adenocarcinomas progression by MAPK/mTOR signaling pathway

Figure 3The alternative text for this image may have been generated using AI.

STAD related target genes and functional analysis. (A) KEGG pathway of related target genes of STAD25. (B) Go enrichment analysis of related target genes of STAD. (C) PPI of related target genes of STAD. (D) The correlation of 2 core genes in STAD patients by GEPIA2 platform. (E) core genes between active ingredients of Croci Stigma and STAD-Venn diagram.

Back to article page